Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer by the targeted killing of cancer stem cells,
today announced two poster presentations at the Society for
Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting &
Associated Programs being held November 4-8, in National Harbor,
Maryland.
The details of the presentations at SITC are as follows:
Title: Targeting Focal Adhesion Kinase Reprograms the Pancreatic
Tumor Microenvironment and Renders Pancreas Cancer Responsive to
Checkpoint Immunotherapy
Date and time: Friday Nov. 6 from
12:30 – 2:00 PM ET
Track: Tumor Microenvironment
Poster
#: 419
Title: FAK/PYK2 Inhibitors Defactinib and VS-4718 Enhance Immune
Checkpoint Inhibitor Efficacy
Date and time: Friday Nov. 6
from 12:30 – 2:00 PM ET
Track: Optimizing Combination
Immunotherapy
Poster #: 371
The posters will be on display starting at 3:00pm ET on Thursday,
November 5th and will remain accessible through 2:00pm ET on
Saturday, November 7th. The posters will also be available on
Verastem’s website at http://bit.ly/R3M6wc
starting at 6:00pm ET on Thursday, November 5th.
About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target
cancer stem cells through the potent inhibition of focal adhesion kinase
(FAK). Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research has
demonstrated that FAK activity is critical for the growth and survival
of cancer stem cells. VS-6063 is currently being studied in the “Window
of Opportunity” study in patients with mesothelioma prior to surgery, a
Phase 1/1b study in combination with paclitaxel in patients with ovarian
cancer, a trial in patients with KRAS-mutated non-small cell lung cancer
and a trial evaluating the combination of VS-6063 and VS-5584 in
patients with relapsed mesothelioma.
About VS-4718
VS-4718 is an orally available compound designed to target cancer stem
cells through the potent inhibition of focal adhesion kinase (FAK).
VS-4718 is currently being studied in a Phase 1 dose escalation study in
patients with advanced cancers.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to
treat cancer by the targeted killing of cancer stem cells. Cancer stem
cells are an underlying cause of tumor recurrence and metastasis.
Verastem is developing small molecule inhibitors of signaling pathways
that are critical to cancer stem cell survival and proliferation: FAK
and PI3K/mTOR. For more information, please visit www.verastem.com.
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development and activity of the Company’s product
candidates, VS-6063 and VS-4718, and the Company’s FAK program
generally, and the potential for combination of FAK inhibitors with
immuno-oncology agents. The words “anticipate,” “appear,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue,”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Each forward-looking statement is subject to risks
and uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks and
uncertainties include the risks that the preclinical testing of the
Company’s product candidates and preliminary or interim data from
clinical trials may not be predictive of the results or success of
ongoing or later clinical trials, that data may not be available when we
expect it to be, that enrollment of clinical trials may take longer than
expected, that our product candidates will cause unexpected safety
events, that the Company will be unable to successfully initiate or
complete the clinical development of its product candidates, that the
development of the Company’s product candidates will take longer or cost
more than planned, and that the Company’s product candidates will not
receive regulatory approval or become commercially successful products.
Other risks and uncertainties include those identified under the heading
“Risk Factors” in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2014 and in any subsequent SEC filings. The
forward-looking statements contained in this press release reflect the
Company’s current views with respect to future events, and the Company
does not undertake and specifically disclaims any obligation to update
any forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151104005241/en/
Copyright Business Wire 2015